vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and CARRIAGE SERVICES INC (CSV). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $105.5M, roughly 1.3× CARRIAGE SERVICES INC). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 11.6%, a 23.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 8.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $6.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 1.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Jardine Cycle & Carriage Limited is the investment holding company of Jardines in Southeast Asia. It is currently 75% held by the conglomerate.
ADMA vs CSV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $105.5M |
| Net Profit | $49.4M | $12.3M |
| Gross Margin | 63.8% | 34.8% |
| Operating Margin | 45.1% | 23.3% |
| Net Margin | 35.5% | 11.6% |
| Revenue YoY | 18.4% | 8.0% |
| Net Profit YoY | -55.9% | 24.5% |
| EPS (diluted) | $0.20 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $105.5M | ||
| Q3 25 | $134.2M | $102.7M | ||
| Q2 25 | $122.0M | $102.1M | ||
| Q1 25 | $114.8M | $107.1M | ||
| Q4 24 | $117.5M | $97.7M | ||
| Q3 24 | $119.8M | $100.7M | ||
| Q2 24 | $107.2M | $102.3M | ||
| Q1 24 | $81.9M | $103.5M |
| Q4 25 | $49.4M | $12.3M | ||
| Q3 25 | $36.4M | $6.6M | ||
| Q2 25 | $34.2M | $11.7M | ||
| Q1 25 | $26.9M | $20.9M | ||
| Q4 24 | $111.9M | $9.9M | ||
| Q3 24 | $35.9M | $9.9M | ||
| Q2 24 | $32.1M | $6.3M | ||
| Q1 24 | $17.8M | $7.0M |
| Q4 25 | 63.8% | 34.8% | ||
| Q3 25 | 56.3% | 35.3% | ||
| Q2 25 | 55.1% | 35.2% | ||
| Q1 25 | 53.2% | 35.3% | ||
| Q4 24 | 53.9% | 34.4% | ||
| Q3 24 | 49.8% | 35.2% | ||
| Q2 24 | 53.6% | 36.2% | ||
| Q1 24 | 47.8% | 36.0% |
| Q4 25 | 45.1% | 23.3% | ||
| Q3 25 | 38.0% | 17.0% | ||
| Q2 25 | 35.1% | 23.5% | ||
| Q1 25 | 30.4% | 29.5% | ||
| Q4 24 | 32.6% | 21.6% | ||
| Q3 24 | 33.1% | 22.7% | ||
| Q2 24 | 36.6% | 18.0% | ||
| Q1 24 | 26.7% | 18.8% |
| Q4 25 | 35.5% | 11.6% | ||
| Q3 25 | 27.1% | 6.4% | ||
| Q2 25 | 28.1% | 11.5% | ||
| Q1 25 | 23.4% | 19.5% | ||
| Q4 24 | 95.2% | 10.1% | ||
| Q3 24 | 30.0% | 9.8% | ||
| Q2 24 | 29.9% | 6.1% | ||
| Q1 24 | 21.7% | 6.7% |
| Q4 25 | $0.20 | $0.76 | ||
| Q3 25 | $0.15 | $0.41 | ||
| Q2 25 | $0.14 | $0.74 | ||
| Q1 25 | $0.11 | $1.34 | ||
| Q4 24 | $0.45 | $0.62 | ||
| Q3 24 | $0.15 | $0.63 | ||
| Q2 24 | $0.13 | $0.40 | ||
| Q1 24 | $0.08 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $1.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $254.8M |
| Total Assets | $624.2M | $1.3B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $1.7M | ||
| Q3 25 | $61.4M | $1.2M | ||
| Q2 25 | $90.3M | $1.4M | ||
| Q1 25 | $71.6M | $4.6M | ||
| Q4 24 | $103.1M | $1.2M | ||
| Q3 24 | $86.7M | $1.3M | ||
| Q2 24 | $88.2M | $1.5M | ||
| Q1 24 | $45.3M | $1.7M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $254.8M | ||
| Q3 25 | $431.2M | $242.1M | ||
| Q2 25 | $398.3M | $235.4M | ||
| Q1 25 | $373.4M | $223.1M | ||
| Q4 24 | $349.0M | $208.6M | ||
| Q3 24 | $231.9M | $198.1M | ||
| Q2 24 | $188.3M | $187.9M | ||
| Q1 24 | $153.7M | $179.6M |
| Q4 25 | $624.2M | $1.3B | ||
| Q3 25 | $568.7M | $1.3B | ||
| Q2 25 | $558.4M | $1.3B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.3B | ||
| Q2 24 | $376.4M | $1.3B | ||
| Q1 24 | $350.9M | $1.3B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $14.1M |
| Free Cash FlowOCF − Capex | $34.6M | $6.2M |
| FCF MarginFCF / Revenue | 24.8% | 5.9% |
| Capex IntensityCapex / Revenue | 0.8% | 7.5% |
| Cash ConversionOCF / Net Profit | 0.72× | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $40.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $14.1M | ||
| Q3 25 | $13.3M | $24.7M | ||
| Q2 25 | $21.1M | $8.1M | ||
| Q1 25 | $-19.7M | $13.8M | ||
| Q4 24 | $50.2M | $9.3M | ||
| Q3 24 | $25.0M | $20.9M | ||
| Q2 24 | $45.6M | $2.2M | ||
| Q1 24 | $-2.2M | $19.7M |
| Q4 25 | $34.6M | $6.2M | ||
| Q3 25 | $-1.1M | $18.0M | ||
| Q2 25 | $18.7M | $5.2M | ||
| Q1 25 | $-24.4M | $10.6M | ||
| Q4 24 | $47.5M | $4.9M | ||
| Q3 24 | $24.0M | $16.2M | ||
| Q2 24 | $43.6M | $-1.4M | ||
| Q1 24 | $-4.6M | $16.2M |
| Q4 25 | 24.8% | 5.9% | ||
| Q3 25 | -0.8% | 17.5% | ||
| Q2 25 | 15.3% | 5.1% | ||
| Q1 25 | -21.2% | 9.9% | ||
| Q4 24 | 40.4% | 5.0% | ||
| Q3 24 | 20.0% | 16.1% | ||
| Q2 24 | 40.7% | -1.4% | ||
| Q1 24 | -5.6% | 15.6% |
| Q4 25 | 0.8% | 7.5% | ||
| Q3 25 | 10.7% | 6.5% | ||
| Q2 25 | 2.0% | 2.8% | ||
| Q1 25 | 4.1% | 3.0% | ||
| Q4 24 | 2.3% | 4.5% | ||
| Q3 24 | 0.9% | 4.6% | ||
| Q2 24 | 1.9% | 3.5% | ||
| Q1 24 | 2.9% | 3.4% |
| Q4 25 | 0.72× | 1.15× | ||
| Q3 25 | 0.36× | 3.76× | ||
| Q2 25 | 0.62× | 0.69× | ||
| Q1 25 | -0.73× | 0.66× | ||
| Q4 24 | 0.45× | 0.94× | ||
| Q3 24 | 0.70× | 2.11× | ||
| Q2 24 | 1.42× | 0.34× | ||
| Q1 24 | -0.12× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
